AMRX vs BMRN
AMRX: A diversified biopharmaceutical company providing a broad range of generic, branded, and specialty medicines alongside pharmaceutical distribution services. BMRN: BioMarin is a biotechnology leader dedicated to transforming the lives of patients with rare, genetically defined diseases through innovative, category-defining medicines.
Side-by-side fundamentals
| Metric | AMRX | BMRN | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $18.14 | $63.81 | |
| Market cap as of 2026-08-09 | $5.8B | $12.4B | |
| P/E as of 2026-08-09 | 47.44 | 45.89 | BMRN lower |
| PEG as of 2026-08-09 | 2.85 | 0.67 | BMRN lower |
| Net margin as of 2026-08-09 | +4.0% | +8.3% | BMRN higher |
| Gross margin as of 2026-08-09 | +38.7% | +80.2% | BMRN higher |
| Operating margin as of 2026-08-09 | +14.3% | +9.7% | AMRX higher |
| ROE as of 2026-08-09 | -34.9% | +4.4% | BMRN higher |
| ROA as of 2026-08-09 | +3.4% | +3.4% | BMRN higher |
| Debt / equity as of 2026-08-09 | 136.58 | 0.23 | BMRN lower |
| Revenue growth (YoY) as of 2026-08-09 | +7.6% | +9.9% | BMRN higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +15.4% | BMRN higher |
| Beta as of 2026-08-09 | 1.24 | 0.21 | |
| 1-year return as of 2026-08-07 close | +121.0% | +7.3% | AMRX higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.